Table 5

14 orphan medicines have (had) market exclusivity surpassing 10 years (not counting possible extensions after filing a paediatric investigation plan)

TradenameFirst authorisation in the EULast authorisation in the EUTotal duration of market exclusivity (years)Annual revenue at time of latest authorisation (million euros)
Soliris22 Jun 200728 Aug 201922.183.500
Revlimid19 Jun 200712 Jul 201619.066.210
Carbaglu28 Jan 20031 Jun 201118.347
Vyndaqel18 Nov 201119 Feb 202018.25421
Nexavar21 Jul 200627 May 201417.85736
Zavesca21 Nov 200228 Jan 200916.1935
Ofev19 Jan 201520 Apr 202015.251.500
Adcetris30 Oct 201219 Dec 201715.14289
Tracleer17 May 200211 Jun 200715.07697
Glivec12 Nov 20011 Dec 200615.051.500
Signifor27 Apr 201221 Nov 201412.57-
Yondelis20 Sep 200730 Oct 200912.11-
Gazyvaro24 Jul 201415 Jun 201611.89179
Torisel21 Nov 200725 Aug 200911.76-
Imbruvica23 Oct 20147 Jul 201510.711.200